Abstract

Objective(s): Normoxic MAGIC-f polymer gels are established dosimeters used for three dimensional dose quantifications in radiotherapy. Nanoparticles with high atomic number such as gold are novel radiosensitizers used to enhance doses delivered to tumors. The aim of this study was to investigate the effect of gold nanoparticles (GNPs) in enhancing percentage depth doses (PDDs) within the MAGIC-f gel exposed to linear accelerator (linac) high energy photon beams. Materials and Methods: The MAGIC-f gel was fabricated based on its standard composition with some modifications. The PDDs in tubes containing the gel were calculated by using a common Monte Carlo code (Geant4) followed by experimental verifications. Then, GNPs with an average diameter of 15 nm and a concentration of 0.1 mM were embedded in the gel, poured into falcon tubes and irradiated with 18 MeV beams of an Elekta linac. Finally, similar experimental and Monte Carlo (MC) calculations were made to determine the effect of using GNPs on some dosimetric parameters of interest.Results: The results of experimental measurements and simulated MC calculations showed a dose enhancement factor (DEF) of 1.12±0.08 and 1.13±0.04, respectively due to the use of GNPs when exposed to 18 MeV linac energies.Conclusion: The results indicated that the fabricated MAGIC-f gel could be recommended as a suitable tool for three dimensional dosimetric investigations at high energy radiotherapy procedures wherein GNPs are used.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.